- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05778032
Biologisk åldersbedömning hos vuxna med Prader-Willis syndrom (ETABIOLPWS) (ETABIOLPWS)
Biologisk åldersbedömning hos vuxna med Prader-Willis syndrom som genomgår ett integrerat multidisciplinärt metabolisk rehabiliteringsprogram
The primary objective of the study is to compare, in a cohort of obese subjects with PWS hospitalized at the Division of Auxology, Istituto Auxologico Italiano, Piancavallo (VB), Italy, the age acceleration calculated at study entry (T0) with the age acceleration measured at the end of a 3-week multidisciplinary metabolic rehabilitation program (T1).
Secondary objectives are to correlate the biological age with the anthropometric characteristics (with particular reference to the body composition), the glycometabolic picture, the main parameters and cardiovascular risk factors, the therapy (previous and concomitant) with rhGH and the cognitive function (mainly, the IQ).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Methods Thirty adults affected by clinically diagnosed and genetically confirmed PWS are recruited, regardless of the treatment (previous or concomitant) with rhGH (F/M = 15/15; age: ≥ 18 years; BMI > 35 kg/m2), hospitalized for a period of integrated multidisciplinary metabolic rehabilitation at the Division of Auxology, Istituto Auxologico Italiano, Piancavallo (VB), Italy.
After verifying the inclusion criteria, clinical and anthropometric data will be collected, including the evaluation of body composition with bioimpedance analysis. Cognitive function will be assessed with a psychometric scale (Wechsler Adult Intelligence Scale).
Blood samples will be taken from each patient upon admission to the hospital (T0) and after 3 weeks of rehabilitation hospitalization (at the same time to reduce circadian variability) for the determination of the basal glycometabolic profile (glucose, insulin, HOMA-IR, glycated Hb , triglycerides, total cholesterol, LDL, HDL, and hsPCR), as well as circulating levels of leptin, IL-6, and TNF-α.
The samples taken will be used for DNA extraction. DNA methylation will be performed by treatment with sodium bisulphite and PCR-Pyrosequencing.
Biological age measurement Biological (epigenetic) age will be measured using the two algorithms of Zbiec-Piekarska (9) and Daunay (10), based on the level of DNA methylation in specific gene loci. To have an estimate of the epigenetic (biological) age that is independent of the chronological age, we will use a measure defined as age acceleration, from which, with statistical inference, we will calculate the age acceleration. To calculate it, a linear regression model with the chronological age as the independent variable and the epigenetic age as the dependent variable will be applied; the difference between the observed value and the one predicted by the model will constitute the age acceleration due to epigenetic effects. In the event that the epigenetic age is greater than the chronological age, the age acceleration will have a positive value expressed in years, negative if vice versa.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Verbania
-
Oggebbio, Verbania, Italien, 28824
- Istituto Auxologico Italiano IRCCS, Site Piancavallo
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Adult patients with Prader-Willi syndrome with BMI > 35 kg/m2
Beskrivning
Inclusion Criteria:
- adult patients with PWS, clinically diagnosed and genetically confirmed, regardless of rhGH treatment (previous or concomitant)
- age: ≥ 18 years
- BMI > 35 kg/m2
- hospitalization for integrated multidisciplinary metabolic rehabilitation program
Exclusion Criteria:
- age < 18 years
- BMI < 35 kg/m2
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
DNA methylation
Tidsram: Baseline and at the end of the rehabilitation program (21 days)
|
Change in level of DNA methylation |
Baseline and at the end of the rehabilitation program (21 days)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Glycometabolic profile: glucose
Tidsram: Baseline and at the end of the rehabilitation program (21 days)
|
Change in glycometabolic profile - glucose levels |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Glycometabolic profile: insulin
Tidsram: Baseline and at the end of the rehabilitation program (21 days)
|
Change in glycometabolic profile - insulin levels |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Body fat mass
Tidsram: Baseline and at the end of the rehabilitation program (21 days)
|
Change in body fat mass - bioimpedance analysis |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Body fat free mass
Tidsram: Baseline and at the end of the rehabilitation program (21 days)
|
Change in body fat free mass - bioimpedance analysis |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Body weight
Tidsram: Baseline and at the end of the rehabilitation program (21 days)
|
Change in body weight |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Body mass index
Tidsram: Baseline and at the end of the rehabilitation program (21 days)
|
Change in body mass index |
Baseline and at the end of the rehabilitation program (21 days)
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Imprinting störningar
- Neurologiska manifestationer
- Sjukdomar i nervsystemet
- Näringsstörningar
- Genetiska sjukdomar, medfödda
- Övernäring
- Kroppsvikt
- Neurobehavioral manifestationer
- Medfödda abnormiteter
- Avvikelser, flera
- Övervikt
- Intellektuell funktionsnedsättning
- Kromosomstörningar
- Medfödda, ärftliga och neonatala sjukdomar och abnormiteter
- Patologiska tillstånd, tecken och symtom
- Närings- och metabola sjukdomar
- Tecken och symtom
- Fetma
- Prader-Willis syndrom
Andra studie-ID-nummer
- 01C213
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .